David Hipkiss

David Hipkiss is an accomplished executive in the life sciences sector with extensive experience in leadership roles across various companies. Currently serving as Executive Chair at AlveoGene since July 2023 and Independent Non-Executive Chair at Rinri Therapeutics, along with being the CEO and Founder of Hippocampus Pharma, a consultancy specializing in business development and strategy. Previous notable positions include co-founding Enesi Pharma, where innovative vaccine delivery technologies were developed, and serving as Chief Business Officer at Circassia, leading significant M&A and licensing activities. Earlier roles include CEO at Prosonix Ltd, Global Licensing Director at Accentus, and Worldwide Business Development Director at Chirotech Technology Limited. David Hipkiss holds a BEng (Hons) in Chemical Engineering from the University of Birmingham.